# [Feline Toxoplasmosis](/knowledge/parasites/pet-parasites/cat-toxoplasmosis-symptoms-in-humans): Neurological Manifestations and Fecal Transmission

## Key Takeaways

- Feline toxoplasmosis, caused by *Toxoplasma gondii*, is characterized by fecal transmission of environmentally resistant oocysts shed by definitive feline hosts.
- Neurological manifestations in cats can range from seizures and ataxia to behavioral changes and blindness, often resulting from tachyzoite invasion of the central nervous system.
- Risk factors for feline toxoplasmosis include outdoor access, hunting, and raw meat consumption, with co-infection by FIV or FeLV significantly increasing the risk of severe disease, including neurological involvement.
- Diagnosis relies on a combination of serological assays (IgG, IgM ELISA), molecular methods (PCR on blood, CSF, or feces), and clinical signs, with recombinant antigens like MIC17A showing promise for feline-specific detection.
- Treatment typically involves clindamycin (10-12 mg/kg q12h for 2-4 weeks) or a sulfadiazine/trimethoprim combination, with prognosis guarded in immunocompromised individuals.
- Prevention strategies focus on minimizing environmental contamination through daily litter box cleaning, feeding cooked diets, and preventing cats from hunting, thereby reducing the risk of oocyst shedding and subsequent infection.

---

## Introduction

[Toxoplasma gondii](/knowledge/parasites/protozoa/toxoplasma-gondii-lifecycle-neurological-infection) is an obligate intracellular apicomplexan parasite that infects virtually all warm-blooded vertebrates [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>]. Felids, including domestic cats, serve as the definitive hosts in which the sexual phase of the life cycle occurs, leading to the excretion of environmentally resistant oocysts [<a href="#ref-1">1</a>, <a href="#ref-3">3</a>]. This unique role makes cats central to the epidemiology of [toxoplasmosis](/knowledge/parasites/pet-parasites/toxoplasmosis-feline-transmission-public-health-clinical-management) [<a href="#ref-4">4</a>]. Feline infection can result in a spectrum of clinical outcomes ranging from subclinical carriage to severe systemic disease, with neurological involvement being a particularly important manifestation [<a href="#ref-5">5</a>, <a href="#ref-6">6</a>, <a href="#ref-7">7</a>]. Fecal transmission of oocysts, commonly referred to as [toxoplasmosis in cat poop](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-etiology-transmission-zoonotic-risk), represents the primary route of environmental contamination and subsequent infection of intermediate hosts [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>, <a href="#ref-3">3</a>]. This reference article provides an exhaustive review of the neurological manifestations and fecal transmission of [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-cat-parasite-reference), incorporating recent advances in diagnostics and an understanding of pathogenetic mechanisms.

## Etiology and Life Cycle

T. gondii exists in three infectious stages: tachyzoites (rapidly dividing), bradyzoites (slowly dividing within tissue cysts), and sporozoites (within oocysts) [<a href="#ref-1">1</a>, <a href="#ref-8">8</a>]. Cats typically acquire infection by ingesting tissue cysts containing bradyzoites from infected prey or raw meat [<a href="#ref-3">3</a>, <a href="#ref-8">8</a>]. After ingestion, bradyzoites excyst in the small intestine and invade enterocytes, initiating an enteroepithelial cycle that culminates in the production of oocysts [<a href="#ref-2">2</a>, <a href="#ref-9">9</a>]. This sexual replication is restricted to the feline intestinal tract [<a href="#ref-1">1</a>]. Oocysts are shed unsporulated in feces and sporulate in the environment within 1 to 5 days, becoming infectious [<a href="#ref-3">3</a>, <a href="#ref-4">4</a>]. Sporulated oocysts can survive for months under favorable conditions [<a href="#ref-4">4</a>]. Concurrently, the parasite may disseminate via the lymphatics and blood as tachyzoites, invading diverse tissues including the brain, muscle, and eyes [<a href="#ref-5">5</a>, <a href="#ref-7">7</a>]. In immunocompetent cats, immune pressure drives conversion to bradyzoites, forming tissue cysts that persist for life [<a href="#ref-8">8</a>, <a href="#ref-10">10</a>]. Reactivation of chronic infection can occur during immunosuppression, leading to recrudescent disease [<a href="#ref-10">10</a>, <a href="#ref-11">11</a>, <a href="#ref-12">12</a>].

## Epidemiology

[Feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-cat-parasite-reference) is distributed globally, with seroprevalence varying by geographic region, lifestyle, and diagnostic method [<a href="#ref-3">3</a>, <a href="#ref-13">13</a>, <a href="#ref-14">14</a>]. Studies report seropositivity rates from 8.6% in domiciled kittens to 57.9% in adult stray cats in the United States [<a href="#ref-15">15</a>]. In Kuwait, IgG and IgM prevalence of 60% and 31.7% respectively were documented [<a href="#ref-13">13</a>]. A nationwide study in Greece found 21.8% seropositivity using a rapid immunochromatographic test, with hunting and outdoor access identified as significant risk factors [<a href="#ref-3">3</a>]. Similar risk factors (rural habitat, hunting, raw feeding) have been reported in Brazil [<a href="#ref-16">16</a>, <a href="#ref-17">17</a>], Finland [<a href="#ref-14">14</a>], and Russia [<a href="#ref-18">18</a>]. Age, gender, and retroviral co-infections may influence seroprevalence and clinical expression [<a href="#ref-3">3</a>, <a href="#ref-17">17</a>, <a href="#ref-19">19</a>]. Co-infection with [feline immunodeficiency virus](/knowledge/viruses/pet-viruses/feline-immunodeficiency-virus) (FIV) or feline leukemia virus (FeLV) is associated with more severe disease and increased risk of neurological [toxoplasmosis](/knowledge/parasites/pet-parasites/toxoplasmosis-feline-transmission-public-health-clinical-management) [<a href="#ref-11">11</a>, <a href="#ref-12">12</a>, <a href="#ref-19">19</a>].

## Neurological Manifestations: [Cat Toxoplasmosis Brain](/knowledge/parasites/pet-parasites/toxoplasmosis-cats-brain-infection-humans)

Neurological involvement in [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-cats), often termed [cat toxoplasmosis brain](/knowledge/parasites/pet-parasites/toxoplasmosis-cats-brain-infection-humans), can result from primary infection or reactivation of latent cysts [<a href="#ref-5">5</a>, <a href="#ref-6">6</a>, <a href="#ref-12">12</a>]. Tachyzoites invade the central nervous system (CNS) by crossing the blood-brain barrier, either as free parasites or within infected leukocytes [<a href="#ref-7">7</a>]. Once in the brain parenchyma, they cause focal necrosis, microglial nodules, and perivascular inflammation [<a href="#ref-7">7</a>, <a href="#ref-12">12</a>]. Clinical signs reflect the location and extent of lesions [<a href="#ref-5">5</a>, <a href="#ref-6">6</a>].

Common neurological signs include seizures (generalized or partial), ataxia, circling, head pressing, behavioral changes (aggression, depression), blindness, and proprioceptive deficits [<a href="#ref-5">5</a>, <a href="#ref-6">6</a>, <a href="#ref-20">20</a>]. Meningoencephalitis may manifest with fever, hyperesthesia, and cranial nerve deficits [<a href="#ref-7">7</a>, <a href="#ref-20">20</a>]. Spinal cord involvement can cause paresis or paralysis [<a href="#ref-7">7</a>]. In a series of 15 clinical cases, neurological signs were present in 7 cats, with 5 showing seizures [<a href="#ref-6">6</a>]. Cerebral [toxoplasmosis](/knowledge/parasites/pet-parasites/toxoplasmosis-feline-transmission-public-health-clinical-management) has been documented in cats with concurrent retroviral infections, including FIV and FeLV, and in cats with feline infectious peritonitis (FIP) [<a href="#ref-11">11</a>, <a href="#ref-12">12</a>]. Oclacitinib therapy for allergic skin disease in an FIV-positive cat triggered fatal disseminated [toxoplasmosis](/knowledge/parasites/pet-parasites/toxoplasmosis-feline-transmission-public-health-clinical-management) with CNS involvement [<a href="#ref-11">11</a>]. Ocular [toxoplasmosis](/knowledge/parasites/pet-parasites/toxoplasmosis-feline-transmission-public-health-clinical-management), often presenting as anterior uveitis, can accompany neurological disease [<a href="#ref-21">21</a>]. In a study of 60 seropositive cats with ocular signs, 63% had anterior uveitis and 20% had posterior segment involvement [<a href="#ref-21">21</a>].

## Pathological Findings

Gross pathological changes in the brain may be absent even in severe cases [<a href="#ref-7">7</a>]. Histologically, the hallmark is multifocal necrotizing encephalitis with areas of gliosis and perivascular cuffing by mononuclear cells [<a href="#ref-7">7</a>, <a href="#ref-12">12</a>]. Free tachyzoites and tissue cysts can be identified within neurons, astrocytes, and microglial cells [<a href="#ref-7">7</a>]. In immunocompromised cats, lesions are more extensive and contain larger numbers of tachyzoites [<a href="#ref-11">11</a>, <a href="#ref-12">12</a>]. A case of cerebral toxoplasmosis in a cat co-infected with FeLV and FIP revealed numerous tachyzoites in the cerebrum, cerebellum, and brainstem, with minimal inflammatory response [<a href="#ref-12">12</a>]. Spinal cord lesions include myelitis and necrosis [<a href="#ref-7">7</a>].

## Fecal Transmission: [Toxoplasmosis in Cat Poop](/knowledge/parasites/pet-parasites/toxoplasma-gondii-in-cats-zoonotic-transmission-clinical-management)

The shedding of oocysts in feces is the defining feature of [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-cats) from a transmission perspective [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>, <a href="#ref-4">4</a>]. After primary infection with bradyzoites, cats begin shedding oocysts within 3 to 10 days, and shedding typically persists for 1 to 3 weeks [<a href="#ref-8">8</a>, <a href="#ref-9">9</a>]. Oocyst output can be enormous: millions per day [<a href="#ref-4">4</a>]. Shedding is often subclinical and transient, making detection challenging [<a href="#ref-1">1</a>, <a href="#ref-15">15</a>]. Cats can also re-shed oocysts after reinfection, though immunity reduces the likelihood [<a href="#ref-10">10</a>, <a href="#ref-22">22</a>]. Tachyzoite or oocyst ingestion may also induce shedding, albeit with different dynamics [<a href="#ref-9">9</a>].

Once shed, sporulated oocysts contaminate soil, water, and surfaces [<a href="#ref-3">3</a>, <a href="#ref-4">4</a>]. They are highly resistant to environmental conditions and can survive for months to years [<a href="#ref-4">4</a>]. Fecal contamination of [cat litter](/knowledge/veterinary-medicine/clinical-methods/cat-litter) boxes, gardens, and sandboxes poses a risk for intermediate hosts, including humans [<a href="#ref-3">3</a>]. Studies examining [toxoplasmosis in cat poop](/knowledge/parasites/pet-parasites/toxoplasmosis-cats-fecal-shedding-zoonotic-risk) have found low oocyst detection rates in natural populations due to intermittent shedding [<a href="#ref-15">15</a>, <a href="#ref-23">23</a>]. However, molecular detection using PCR has improved sensitivity for identifying oocysts in fecal samples [<a href="#ref-1">1</a>].

## Diagnostic Approaches

Accurate diagnosis of [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-clinical-management-zoonotic-risks-brazil) requires integration of serological, molecular, and clinical data [<a href="#ref-1">1</a>, <a href="#ref-24">24</a>, <a href="#ref-25">25</a>]. Serological assays detect IgG and IgM antibodies. IgG indicates past or chronic infection; IgM suggests recent or active infection [<a href="#ref-13">13</a>, <a href="#ref-21">21</a>]. Commercially available immunochromatographic tests provide rapid point-of-care results, but their sensitivity and specificity vary [<a href="#ref-3">3</a>, <a href="#ref-13">13</a>]. Enzyme-linked immunosorbent assay (ELISA) using tachyzoite lysate antigen (TLA) is a reference method, but recombinant antigens offer safer, standardized alternatives [<a href="#ref-26">26</a>]. Microneme protein 17A (MIC17A) is highly expressed in merozoites (enteroepithelial stages) and has been proposed as a diagnostic marker specific for feline infection [<a href="#ref-2">2</a>, <a href="#ref-27">27</a>]. Recombinant antigens including SAG2, GRA2, GRA6, GRA7, GRA15, and MIC10 have been evaluated in combination, achieving performance comparable to TLA [<a href="#ref-26">26</a>].

Molecular methods (PCR) detect T. gondii DNA in blood, cerebrospinal fluid (CSF), aqueous humor, or feces [<a href="#ref-1">1</a>, <a href="#ref-21">21</a>]. PCR is particularly useful for confirming active infection and for detecting oocysts in feces [<a href="#ref-1">1</a>]. Emerging nanomaterial-enhanced assays and artificial intelligence-based diagnostic algorithms promise to improve stage-specific detection [<a href="#ref-1">1</a>]. The diagnostic decision tree is illustrated in Figure 1.

```mermaid
flowchart TD
 A["Clinical suspicion of feline toxoplasmosis"] --> B{"Neurological signs?"}
 B -->|"Yes"| C["CSF analysis: PCR + antibody index"]
 B -->|"No"| D{"Ocular signs?"}
 D -->|"Yes"| E["Aqueous humor PCR + serology"]
 D -->|"No"| F["Serology: IgG & IgM ELISA"]
 C --> G["Positive PCR or elevated antibody index?"]
 G -->|"Yes"| H["Probable CNS toxoplasmosis"]
 G -->|"No"| I["Consider other causes"]
 E --> J["Positive PCR or local antibody production?"]
 J -->|"Yes"| K["Probable ocular toxoplasmosis"]
 J -->|"No"| L["Other uveitis etiology"]
 F --> M{"IgM positive or rising IgG?"}
 M -->|"Yes"| N["Active infection - treat"]
 M -->|"No"| O["Chronic infection - assess risk factors"]
 N --> P["Fecal PCR for oocyst shedding"]
 P --> Q["Positive: environmental contamination risk"]
 P --> R["Negative: no active shedding"]
```

Table 1 summarizes the main diagnostic methods and their characteristics.

| Method | Target | Sensitivity | Specificity | Stage Detected | Reference |
|----|----|-------|-------|--------|------|
| IgG ELISA (TLA) | Anti-T. gondii IgG | High | High | Chronic/any | [<a href="#ref-26">26</a>] |
| IgM ELISA | Anti-T. gondii IgM | Moderate | Moderate | Recent/active | [<a href="#ref-13">13</a>, <a href="#ref-21">21</a>] |
| Immunochromatographic test | IgG/IgM | Variable | Variable | Chronic/active | [<a href="#ref-3">3</a>, <a href="#ref-13">13</a>] |
| Recombinant antigen ELISA (MIC17A) | IgG | High | High (feline-specific) | Enteroepithelial/chronic | [<a href="#ref-2">2</a>, <a href="#ref-27">27</a>] |
| PCR (blood, CSF, feces) | T. gondii DNA | High | High | Active infection | [<a href="#ref-1">1</a>, <a href="#ref-21">21</a>] |
| Carbon immunoassay | Antibodies | Moderate | High | Chronic | [<a href="#ref-28">28</a>] |

## Treatment and Management

The cornerstone of treatment for clinical [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-etiology-transmission-zoonotic-risk) is clindamycin, administered orally or parenterally at 10 to 12 mg/kg every 12 hours for 2 to 4 weeks [<a href="#ref-6">6</a>, <a href="#ref-24">24</a>]. A combination of sulfadiazine and trimethoprim is also used [<a href="#ref-21">21</a>, <a href="#ref-29">29</a>]. In a study of 15 clinical cases, 13 cats responded to clindamycin therapy within 48 hours [<a href="#ref-6">6</a>]. Ocular toxoplasmosis may require additional topical corticosteroids or mydriatics [<a href="#ref-21">21</a>]. Immunocompromised cats, such as those with FIV or FeLV, may require prolonged therapy and guarded prognosis [<a href="#ref-11">11</a>, <a href="#ref-19">19</a>]. In one case, oclacitinib therapy was associated with fatal toxoplasmosis, indicating caution with immunosuppressive drugs in seropositive cats [<a href="#ref-11">11</a>]. Supportive care includes fluid therapy, nutritional support, and anticonvulsants for seizure control [<a href="#ref-6">6</a>, <a href="#ref-24">24</a>]. Phosprenyl (polyprenyl phosphate) has been studied in cats with concurrent coronavirus infection and toxoplasmosis, showing improvement in hematologic and biochemical parameters [<a href="#ref-29">29</a>]. Long-term management aims to prevent recrudescence: minimizing stress, avoiding immunosuppressive agents, and maintaining good nutrition [<a href="#ref-10">10</a>, <a href="#ref-24">24</a>].

## Control and Prevention

Given the central role of fecal transmission, control of [toxoplasmosis in cats](/knowledge/bacteria/pet-parasites/toxoplasmosis-cats-zoonotic-risk-pregnancy) focuses on reducing environmental contamination with oocysts ([toxoplasmosis in cat poop](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-etiology-transmission-zoonotic-risk)) [<a href="#ref-4">4</a>, <a href="#ref-30">30</a>]. Key measures include: (1) preventing cats from hunting by keeping them indoors or using bells; (2) feeding only cooked or commercial diets; (3) daily cleaning of litter boxes (oocysts require 1 to 5 days to sporulate); (4) careful disposal of cat feces; and (5) covering children's sandboxes when not in use [<a href="#ref-3">3</a>, <a href="#ref-4">4</a>, <a href="#ref-30">30</a>]. Serologic screening can identify cats that are actively shedding or at risk for reactivation [<a href="#ref-1">1</a>, <a href="#ref-16">16</a>, <a href="#ref-25">25</a>]. Vaccination of cats is not currently widely available, although research continues [<a href="#ref-1">1</a>]. Public education remains essential to mitigate [zoonotic risk](/knowledge/parasites/pet-parasites/zoonotic-risk-humans-get-parasites-from-pets) [<a href="#ref-4">4</a>, <a href="#ref-13">13</a>].

## References

<a id="ref-1"></a>[<a href="#ref-1">1</a>] Zhao D, Liao Y, Liu H, et al. Comprehensive diagnostic approaches to [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-neurological-manifestations-cerebral-involvement): Bridging traditional methods and emerging technologies. *Virulence*. 2025. URL: https://www.semanticscholar.org/paper/2e757aa2ddd10827f80fab2653e009ad1d5e71da

<a id="ref-2"></a>[<a href="#ref-2">2</a>] Chen J, Xue L, Hu H, et al. MIC17A is a novel diagnostic marker for [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-neurological-zoonotic-prevention). *Animal Diseases*. 2022. URL: https://www.semanticscholar.org/paper/409a1c77abdc8102e0ee7ad5b4a222f8efdd3e71

<a id="ref-3"></a>[<a href="#ref-3">3</a>] Sioutas G, Symeonidou I, Gelasakis A, et al. [Feline Toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-neurological-zoonotic-prevention) in Greece: A Countrywide Seroprevalence Study and Associated Risk Factors. *Pathogens*. 2022. URL: https://www.semanticscholar.org/paper/7a38aa6feab78b556c75fca605f426eadd8440c6

<a id="ref-4"></a>[<a href="#ref-4">4</a>] Bresciani K, Galvão AL, Vasconcellos ALD, et al. EPIDEMIOLOGICAL ASPECTS OF [FELINE TOXOPLASMOSIS](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-pathogenesis-diagnosis-zoonotic-implications). 2016. URL: https://www.semanticscholar.org/paper/6b9f21d91d91295b742aef77632d2525479580ce

<a id="ref-5"></a>[<a href="#ref-5">5</a>] Lappin MR, Greene CE, Winston S, et al. Clinical [Feline Toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-pathogenesis-diagnosis-zoonotic-implications). 1989. URL: https://www.semanticscholar.org/paper/1ae2d5c4420cf0ff662e99d9964dc6c34a70036b

<a id="ref-6"></a>[<a href="#ref-6">6</a>] Lappin MR, Greene CE, Winston S, et al. Clinical [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-public-health-implications-clinical-presentation-and-diagnostic-management). Serologic diagnosis and therapeutic management of 15 cases. *Journal of Veterinary Internal Medicine*. 1989. URL: https://www.semanticscholar.org/paper/188e9c7e48fcd3dd733c4dadbdd3bf4a2c1dbf

<a id="ref-7"></a>[<a href="#ref-7">7</a>] Hirth RS, Nielsen SW. Pathology of [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-public-health-implications-clinical-presentation-and-diagnostic-management). *Journal of Small Animal Practice*. 1969. URL: https://www.semanticscholar.org/paper/70ea7aed2b1cd57cf4238050c1395234eaa98dde

<a id="ref-8"></a>[<a href="#ref-8">8</a>] Dubey JP, Frenkel JK. [Feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-risks-pregnant-women-immunocompromised) from acutely infected mice and the development of Toxoplasma cysts. *The Journal of Protozoology*. 1976. URL: https://www.semanticscholar.org/paper/8baf73ffc19ee8034b04927ed5eb249b3daa9e18

<a id="ref-9"></a>[<a href="#ref-9">9</a>] Omata Y, Oikawa H, Kanda M, et al. Experimental [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-toxoplasma-gondii): humoral immune responses of cats inoculated orally with [Toxoplasma gondii](/knowledge/parasites/protozoa/toxoplasma-gondii-lifecycle-neurological-infection) cysts and oocysts. *Nihon Juigaku Zasshi*. 1990. URL: https://www.semanticscholar.org/paper/b51652947e0dfa715c4d08df67cd76221708e926

<a id="ref-10"></a>[<a href="#ref-10">10</a>] Dubey JP, Frenkel JK. Immunity to [Feline Toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-zoonotic-implications-clinical-management): Modification by Administration of Corticosteroids. *Veterinary Pathology-Supplement*. 1974. URL: https://www.semanticscholar.org/paper/7d02cb1226cf6abea11de16a6dd851250bc20241

<a id="ref-11"></a>[<a href="#ref-11">11</a>] Moore A, Burrows A, Malik R, et al. Fatal disseminated toxoplasmosis in a [feline immunodeficiency virus](/knowledge/viruses/pet-viruses/feline-immunodeficiency-virus)-positive cat receiving oclacitinib for feline atopic skin syndrome. *Veterinary Dermatology*. 2022. URL: https://www.semanticscholar.org/paper/c931267329077e9f22210c3439872dddff053542

<a id="ref-12"></a>[<a href="#ref-12">12</a>] Zandonà L, Brunetta R, Zanardello C, et al. Cerebral toxoplasmosis in a cat with feline leukemia and feline infectious peritonitis viral infections. *The Canadian Veterinary Journal*. 2018. URL: https://www.semanticscholar.org/paper/9b883ef30868dedf42a1c8dc0e77da44dfe0abb2

<a id="ref-13"></a>[<a href="#ref-13">13</a>] Ibrahim SM, Mohamed I, Suliman SE, et al. Seroprevalence of [Feline Toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-zoonotic-implications-clinical-management) in Kuwait State. *International Journal of Current Microbiology and Applied Sciences*. 2025. URL: https://www.semanticscholar.org/paper/f05f6b05b012c996ed244740c03869e7e95c3f5b

<a id="ref-14"></a>[<a href="#ref-14">14</a>] Jokelainen P, Simola O, Rantanen E, et al. [Feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-zoonotic-risk-diagnosis-and-management) in Finland. *Journal of Veterinary Diagnostic Investigation*. 2012. URL: https://www.semanticscholar.org/paper/6a4fbacb25ee047707fcc3cc04c3c600dc321216

<a id="ref-15"></a>[<a href="#ref-15">15</a>] Dubey JP. [Feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-zoonotic-risk) and coccidiosis: a survey of domiciled and stray cats. *Journal of the American Veterinary Medical Association*. 1973. URL: https://www.semanticscholar.org/paper/ccb8d11ca9bbfc79aec59433b8a97df0159136cd

<a id="ref-16"></a>[<a href="#ref-16">16</a>] Teixeira J, Oliveira JS, Almeida D, et al. Seroprevalence of [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-zoonotic-risks-clinical-management) in Teresina, Piauí, Brazil. 2016. URL: https://www.semanticscholar.org/paper/b5a75e8076e477c63e0ad3cf290165adcea31440

<a id="ref-17"></a>[<a href="#ref-17">17</a>] Munhoz AD, Hage SB, Cruz R, et al. [Toxoplasmosis in cats](/knowledge/parasites/pet-parasites/cat-toxoplasmosis-neonatal) in northeastern Brazil: Frequency, associated factors and coinfection with Neospora caninum, [feline immunodeficiency virus](/knowledge/viruses/pet-viruses/feline-immunodeficiency-virus) and feline leukemia virus. *Veterinary Parasitology: Regional Studies and Reports*. 2017. URL: https://www.semanticscholar.org/paper/7c8a2fdd2e9561c2569bc4e98397bbe347e630a2

<a id="ref-18"></a>[<a href="#ref-18">18</a>] Sivkova TN, Shchukina AA. [The epizootology of [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-zoonotic-risks-clinical-management) in the town of Perm]. *Meditsinskaia Parazitologiia i Parazitarnye Bolezni*. 2008. URL: https://www.semanticscholar.org/paper/676184d88f61d78e65d2295dde6078cb8874f7e8

<a id="ref-19"></a>[<a href="#ref-19">19</a>] Okewole EA, Akpan MO. Clinical [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-zoonotic-risks-clinical-signs-management): parasitological, haematological and serological findings in retroviral infected and uninfected cats. 2002. URL: https://www.semanticscholar.org/paper/2e27851bb71e0ccb0409282c54991b0237af3d91

<a id="ref-20"></a>[<a href="#ref-20">20</a>] Petrak M, Carpenter J. [FELINE TOXOPLASMOSIS](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-zoonotic-risks-clinical-signs-management). *Journal of the American Veterinary Medical Association*. 1965. URL: https://www.semanticscholar.org/paper/b716bfc934da864c863f7e5d8c3624e2dcc7c73e

<a id="ref-21"></a>[<a href="#ref-21">21</a>] Ali KM, Abu-Seida AM, Abuowarda M. Feline ocular toxoplasmosis: seroprevalence, diagnosis and treatment outcome of 60 clinical cases. *Polish Journal of Veterinary Sciences*. 2021. URL: https://www.semanticscholar.org/paper/0d19fc80bf1bde129d6b11a3e14b5e0b7dc7192c

<a id="ref-22"></a>[<a href="#ref-22">22</a>] Hagiwara T, Katsube Y, Muto T, et al. Experimental [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-zoonotic-risks). *Nihon Juigaku Zasshi*. 1981. URL: https://www.semanticscholar.org/paper/4a9f71a86da7f23dbac805ed17582f5d491c5498

<a id="ref-23"></a>[<a href="#ref-23">23</a>] Dubey JP. [Feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis) and its nematode transmission. 1968. URL: https://www.semanticscholar.org/paper/9739e9c0ebc5b4da8a73d718ce795f65831c9bd1

<a id="ref-24"></a>[<a href="#ref-24">24</a>] Caney S. Update on [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis). 2021. URL: https://www.semanticscholar.org/paper/04388a62c4aa2e740b6e424bd443e7a1366da8e9

<a id="ref-25"></a>[<a href="#ref-25">25</a>] Lappin MR. [Feline toxoplasmosis](/knowledge/parasites/pet-parasites/toxoplasmosis-cats-testing-public-health): interpretation of diagnostic test results. *Seminars in Veterinary Medicine and Surgery*. 1996. URL: https://www.semanticscholar.org/paper/0ebd1635960c3958e8d9abd8d2646094a8be6fd8

<a id="ref-26"></a>[<a href="#ref-26">26</a>] Abdelbaset A, Alhasan H, Salman D, et al. Evaluation of recombinant antigens in combination and single formula for diagnosis of [feline toxoplasmosis](/knowledge/parasites/pet-parasites/cat-toxoplasmosis-symptoms-in-humans). *Experimental Parasitology*. 2017. URL: https://www.semanticscholar.org/paper/1fd2239858e29ce336d8d273dd32e3c1ed51f467

<a id="ref-27"></a>[<a href="#ref-27">27</a>] Günay-Esiyok Ö, Koçkaya ES, Yılmaz R, et al. The Potential of MIC17A both as an Entero-epithelial and Chronic Stage Marker for Detection of [Feline Toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-cat-parasite-reference). *Current Microbiology*. 2026. URL: https://www.semanticscholar.org/paper/170f603aa98f7dd6b215d4a83f5f76f844c9e861

<a id="ref-28"></a>[<a href="#ref-28">28</a>] Pakes SP, Lai W. Carbon immunoassay-a simple and rapid serodiagnostic test for [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-cat-parasite-reference). *Laboratory Animal Science*. 1985. URL: https://www.semanticscholar.org/paper/080360020a814df09eb4c1d8667765bf1f9c6448

<a id="ref-29"></a>[<a href="#ref-29">29</a>] Savoyskaya S, Sanin A, Ogorodnikova I, et al. Phosprenyl usage as part of the complex therapy of feline chronic coronavirus infection complicated by toxoplasmosis. *Russian Veterinary Journal*. 2022. URL: https://www.semanticscholar.org/paper/d2205256d3e3592683ec54c4e85a619eac09add0

<a id="ref-30"></a>[<a href="#ref-30">30</a>] Svoboda M, Konrád J, Svobodová V. [Diagnosis and prevention of [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-cats)]. *Tierarztliche Praxis*. 1988. URL: https://www.semanticscholar.org/paper/0c47806d4447df5d683949639d6bc30766a7b03b

<a id="ref-31"></a>[<a href="#ref-31">31</a>] Faria JL, Couto C, Wierzynski SL, et al. [Feline Toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-cats): Tumor Necrosis Factor, Nitric Oxide, and Free Radicals in Seropositive Cats. *Journal of Parasitology*. 2018. URL: https://www.semanticscholar.org/paper/6949c8c0034df3c74f48a543ed58094bbdee2c85

<a id="ref-32"></a>[<a href="#ref-32">32</a>] Brennan A. Risk factors in [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-clinical-management-zoonotic-risks-brazil). 2018. URL: https://www.semanticscholar.org/paper/f488897999e2e89707722c6d17b4288f318c47a5

<a id="ref-33"></a>[<a href="#ref-33">33</a>] MacKnight KT, Robinson HW. Epidemiologic studies on human and [feline toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-etiology-transmission-zoonotic-risk). 1992. URL: https://www.semanticscholar.org/paper/1f00a302a974f5cfc4ddec180eb6d4e0e52698df

<a id="ref-34"></a>[<a href="#ref-34">34</a>] Mizusawa K, Oosawa K, Thoyama K, et al. Seroepidemiological Survey on [Feline Toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-neurological-manifestations-cerebral-involvement) in Saitama Prefecture. 1991. URL: https://www.semanticscholar.org/paper/c614f887ae21d3ca12a82fdee2f1537273f48508

<a id="ref-35"></a>[<a href="#ref-35">35</a>] Lappin MR. Chapter 28. [Feline Toxoplasmosis](/knowledge/parasites/pet-parasites/feline-toxoplasmosis-neurological-zoonotic-prevention). 2008. URL: https://www.semanticscholar.org/paper/0d5233dd99e8824d4e4e00369f97cc6b0491eefa

## Related Clinical & Scientific Guides

* [Tick-Borne Diseases in Dogs: Pathogens, Clinical Signs, Diagnosis, and Prevention](/knowledge/parasites/general/tick-borne-diseases-dogs)
* [Toxoplasmosis in Cats and the Risk of Brain Infection in Humans](/knowledge/parasites/general/toxoplasmosis-cats-brain-infection-humans)
* [Dog Heartworm and Tick-Borne Disease Prevention](/knowledge/parasites/general/dog-heartworm-and-tick-borne-disease-prevention)